Four new antiglaucomatous drugs: Apractonidine, brimonidine, dorzolamide and latanoprost;Vier nieuwe geneesmiddelen bij glaucoom: Apraclonidine, brimonidine, dorzolamide en latanoprost

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 39, 1998, Pages 2138-2141

  Hoyng, Ph F J ^a,b   Rasker, M T E ^a,b  

^a Interuniv Oogheelkundig Instituut   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; MIOTIC AGENT; PROSTAGLANDIN DERIVATIVE;

DRUG EFFICACY; DRUG INDICATION; DRUG TOLERANCE; GLAUCOMA; HUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; CARBONIC ANHYDRASE INHIBITORS; CLONIDINE; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA; HUMANS; MALE; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; SULFONAMIDES; THIOPHENES;

EID: 0032569392     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res 1971;12:275-81.
2. Bill A. Uveoscleral drainage of aqueous humor: physiology and pharmacology. Prog Clin Biol Res 1989;312:417-27.
3. Kaufman PL, Gabelt BT. Alpha2-adrenergic agonist effects on aqueous humor dynamics. J Glaucoma 1995;4 Suppl:8-14.
4. Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988;95:1217-20.
5. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes Arch Ophthalmol 1995;113:1514-7.
6. Morrison JC, Robin AL. Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology 1989;96:3-7.
7. Robin AL. The role of α-agonists in glaucoma therapy. Curr Opin Ophthalmol 1997,8 42-9.
8. Schuman JS Clinical experience with brimonidine 0.2% and timolol 0 5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41 Suppl 1:S27-37.
9. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol 1996;41 Suppl 1:S39-47.
10. Kitazawa Y Longterm treatment with MK-507, a topical carbonic anhydrase inhibitor. Ophthalmology 1993:100 Suppl.81.
11. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995;113:1009-16.
12. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressures. The Dorzolamide Additivity Study Group. Ophthalmology 1996;103:1283-93.
13. Laibovitz R, Strahlman ER, Barber BL, Strohmaier KM. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995;4:306-13.
14. Caputo BJ, Katz LJ. The quality of life of the glaucoma patient in the light of treatment modalities. Curr Opin Ophthalmol 1994;5:10-4.
15. Nagasubramanian S. Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993;9:1305-11.
16. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52.
17. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma - six month, masked USA multicenter trial. The USA Latanoprost Study Group. Ophthalmology 1995;103:138-47.
18. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899-902
19. Aim A, Widengard I, Kjellgren D, Soderström M, Friström B, Heijl A, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-6.
20. Rulo AH, Greve EL, Hoyng PF. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology 1997;104:1503-7.
21. Hoyng PFJ, Rulo A, Greve E, Watson P, Alm A. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol 1997;41 Suppl 2:S93-8.
22. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111:662-5.
23. Greve EL, Rulo AH, Drance SM, Crichton AC, Mills RP, Hoyng PFJ Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment. Surv Ophthalmol 1997;41 Suppl 2:S89-92.
24. Rulo AH, Greve EL, Geijssen HC, Hoyng PFJ. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103:1276-82.
25. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996,103:126-37.
26. Hu F, Mah K. Changes in melanosomes with age in irtdial stromal melanocytes of rhesus macaques. Mech Ageing Dev 1983;23:95-102.
27. Prota G. Melanins and melanogenesis. San Diego: Academic Press, 1992.